Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NODE-202 pediatric etripamil study
NL-OMON60762Phase 2Not yet recruiting
- Sponsor
- Milestone Pharmaceuticals
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) (2 arms), sponsored by Milestone Pharmaceuticals. Primary endpoint: Conversion to sinus rhythm within 15 minutes. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NL-OMON60762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60762.